Clinical trials: Enteric Hyperoxaluria
Secondary Hyperoxaluria, Nephrolithiasis
A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria
Identify individuals with greater absorption of oxalate based on increase in urinary oxalate excretion in response to a controlled oxalate-rich test meal.
- Conditions
- Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria, Kidney Stones
- Trial name
- NCT03095885
- Testing
- Test Meal
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Allena Pharmaceuticals
Nephrolithiasis, Hyperoxaluria
Use of Oral Probiotics to Reduce Urinary Oxalate Excretion
The purpose of this study was to determine the effect of two probiotic preparations (Agri-King Synbiotic and Oxadrop) on urinary oxalate excretion in patients with mild hyperoxaluria.
- Conditions
- Nephrolithiasis, Hyperoxaluria, Crohn's Disease
- Trial name
- NCT00587041
- Testing
- Oxadrop, Agri-King Synbiotic (AKSB)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Hyperoxaluria, Nephrolithiasis
Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
The purpose of this study is to evaluate the effect of ALLN-177 to reduce urinary oxalate excretion in patients with recurring kidney stones and enteric or idiopathic hyperoxaluria.
- Trial name
- NCT02289755
- Testing
- ALLN-177
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Allena Pharmaceuticals
Hyperoxaluria
Oxazyme in Patients With Hyperoxaluria
Hypothesis: Oral administration of the oxalate metabolizing enzyme Oxazyme (OC4) will degrade food-borne oxalate and hence prevent its absorption from the gastrointestinal tract.
- Trial name
- NCT01127087
- Testing
- Oxazyme
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic